Lokahi Therapeutics renews University of Georgia academic program tie
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
August 21, 2026 8:00 AM EDTRUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lkahi Therapeutics, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgias Student Industry Fellows Program in the ai² Futures Lab. The renewed collaboration expands Lkahis growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked, or strategically deprioritized therapeutic assets. The program functions as a capital-efficient component of Lkahis asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business... More
